Literature DB >> 17514647

Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment.

Christophe Picard1, Monique Silvy, Corinne Gerard, Christophe Buffat, Esteban Lavaque, Dominique Figarella-Branger, Henri Dufour, Jean Gabert, Albert Beckers, Thierry Brue, Alain Enjalbert, Anne Barlier.   

Abstract

Gs alpha, the alpha-subunit of the heterotrimeric GTP-binding protein, is coded from the GNAS gene, which is imprinted in a tissue-specific manner. Gs alpha is paternally silenced in normal pituitary, but Gs alpha imprinting relaxation is found in some tumoral tissue. In addition, Gs alpha mRNA levels are high in some somatotroph adenomas not bearing the active Gs alpha mutant, the gsp oncogene. In this study, the impact of loss of imprinting on Gs alpha expression level and on tumoral phenotype has been investigated. We compared the expression and imprinting of 4 transcripts of GNAS locus (NESP55, XL alpha s, exon 1A, Gs alpha) of 60 somatotroph adenomas with those of 23 lactotroph adenomas. The paternal and maternal transcripts were quantified using allele-specific real-time PCR and FokI polymorphism. Moreover, the methylation of exon 1A DMR was analyzed. As is the case for the gsp oncogene, high Gs alpha expression in gsp- tumors was associated with smaller tumor size and better octreotide sensitivity. A strong imprinting relaxation (percentage of paternal Gs alpha expression >or=7.5%) was found only in gsp- tumors. The loss of Gs alpha imprinting was associated with a decrease in exon 1A mRNA expression. Unexpectedly, the methylation status of exon 1A DMR was not modified in relaxed tumors. Maternal Gs alpha mRNA level decreased with exon 1A level, and consequently the loss of Gs alpha imprinting did not induce the expected Gs alpha overexpression. Finally, XL alpha s mRNA level correlated with that of paternal Gs alpha and of NESP55 showing the complexity of gene regulation in the GNAS locus. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17514647     DOI: 10.1002/ijc.22816

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

Authors:  Laura E MacConaill; Elizabeth Garcia; Priyanka Shivdasani; Matthew Ducar; Ravali Adusumilli; Marc Breneiser; Mark Byrne; Lawrence Chung; Jodie Conneely; Lauren Crosby; Levi A Garraway; Xin Gong; William C Hahn; Charlie Hatton; Philip W Kantoff; Michael Kluk; Frank Kuo; Yonghui Jia; Ruchi Joshi; Janina Longtine; Allison Manning; Emanuele Palescandolo; Nematullah Sharaf; Lynette Sholl; Paul van Hummelen; Jacqueline Wade; Bruce M Wollinson; Dimity Zepf; Barrett J Rollins; Neal I Lindeman
Journal:  J Mol Diagn       Date:  2014-08-23       Impact factor: 5.568

Review 2.  Carney complex and McCune Albright syndrome: an overview of clinical manifestations and human molecular genetics.

Authors:  Paraskevi Salpea; Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2013-09-05       Impact factor: 4.102

3.  Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways.

Authors:  Paraskevi Xekouki; Monalisa Azevedo; Constantine A Stratakis
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

Review 4.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

Review 5.  Drug resistance in pituitary tumours: from cell membrane to intracellular signalling.

Authors:  Erika Peverelli; Donatella Treppiedi; Federica Mangili; Rosa Catalano; Anna Spada; Giovanna Mantovani
Journal:  Nat Rev Endocrinol       Date:  2021-06-30       Impact factor: 43.330

6.  Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses.

Authors:  Chheng-Orn Evans; Carlos S Moreno; Xianquan Zhan; Michael T McCabe; Paula M Vertino; Dominic M Desiderio; Nelson M Oyesiku
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

7.  Study of major genetic factors involved in pituitary tumorigenesis and their impact on clinical and biological characteristics of sporadic somatotropinomas and non-functioning pituitary adenomas.

Authors:  R K Foltran; P V G H Amorim; F H Duarte; I P P Grande; A C T B Freire; F P Frassetto; J B Dettoni; V A Alves; I Castro; E B Trarbach; M D Bronstein; R S Jallad
Journal:  Braz J Med Biol Res       Date:  2018-06-25       Impact factor: 2.590

8.  Impact of SLC20A1 on the Wnt/β‑catenin signaling pathway in somatotroph adenomas.

Authors:  Jianhua Li; Wei Dong; Zhenye Li; Hongyun Wang; Hua Gao; Yazhuo Zhang
Journal:  Mol Med Rep       Date:  2019-08-06       Impact factor: 2.952

9.  The curious case of Gαs gain-of-function in neoplasia.

Authors:  Giulio Innamorati; Thomas M Wilkie; Havish S Kantheti; Maria Teresa Valenti; Luca Dalle Carbonare; Luca Giacomello; Marco Parenti; Davide Melisi; Claudio Bassi
Journal:  BMC Cancer       Date:  2018-03-15       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.